×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
ARVN – arvinas, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
ARVN
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
3/5
02:22 pm
arvn
Arvinas (ARVN) had its price target raised by Citigroup Inc. from $15.00 to $18.00. They now have a "buy" rating on the stock.
Low
Report
Arvinas (ARVN) had its price target raised by Citigroup Inc. from $15.00 to $18.00. They now have a "buy" rating on the stock.
3/4
10:57 am
arvn
Arvinas Highlights Growing Phase 1 Pipeline, Near-Term Catalysts at TD Cowen Healthcare Conference [Yahoo! Finance]
Low
Report
Arvinas Highlights Growing Phase 1 Pipeline, Near-Term Catalysts at TD Cowen Healthcare Conference [Yahoo! Finance]
3/3
10:05 am
arvn
Prostate Cancer Market Competitive Landscape Report 2026: Comprehensive Insights About 230+ Companies and 265+ Drugs by Product Type, Stage, and Route of Administration [Yahoo! Finance]
Low
Report
Prostate Cancer Market Competitive Landscape Report 2026: Comprehensive Insights About 230+ Companies and 265+ Drugs by Product Type, Stage, and Route of Administration [Yahoo! Finance]
3/2
04:10 am
arvn
Arvinas, Inc. (ARVN) Makes Significant Progress on Oncology and Neurology Trials [Yahoo! Finance]
Low
Report
Arvinas, Inc. (ARVN) Makes Significant Progress on Oncology and Neurology Trials [Yahoo! Finance]
3/2
01:00 am
arvn
Arvinas (ARVN) was downgraded by Wall Street Zen from "hold" to "sell
Low
Report
Arvinas (ARVN) was downgraded by Wall Street Zen from "hold" to "sell
2/25
09:39 am
arvn
Arvinas (ARVN) had its "overweight" rating reaffirmed by Piper Sandler. They now have a $20.00 price target on the stock, up from $16.00.
Low
Report
Arvinas (ARVN) had its "overweight" rating reaffirmed by Piper Sandler. They now have a $20.00 price target on the stock, up from $16.00.
2/24
07:03 pm
arvn
Arvinas Inc (ARVN) Q4 2025 Earnings Call Highlights: Navigating Revenue Challenges with ... [Yahoo! Finance]
Medium
Report
Arvinas Inc (ARVN) Q4 2025 Earnings Call Highlights: Navigating Revenue Challenges with ... [Yahoo! Finance]
2/24
03:08 pm
arvn
Arvinas (ARVN) had its "neutral" rating reaffirmed by Wedbush.
Low
Report
Arvinas (ARVN) had its "neutral" rating reaffirmed by Wedbush.
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
3/2
09:01 pm
arvn
Form 4 ARVINAS, INC. For: Feb 26 Filed by: Loomis David K
Low
Report
Form 4 ARVINAS, INC. For: Feb 26 Filed by: Loomis David K
3/2
09:00 pm
arvn
Form 4 ARVINAS, INC. For: Feb 26 Filed by: Berkowitz Noah
Low
Report
Form 4 ARVINAS, INC. For: Feb 26 Filed by: Berkowitz Noah
3/2
09:00 pm
arvn
Form 4 ARVINAS, INC. For: Feb 26 Filed by: Cacace Angela M
Low
Report
Form 4 ARVINAS, INC. For: Feb 26 Filed by: Cacace Angela M
3/2
08:59 pm
arvn
Form 4 ARVINAS, INC. For: Feb 26 Filed by: Saik Andrew
Low
Report
Form 4 ARVINAS, INC. For: Feb 26 Filed by: Saik Andrew
3/2
08:58 pm
arvn
Form 4 ARVINAS, INC. For: Feb 26 Filed by: Teel Randy
Low
Report
Form 4 ARVINAS, INC. For: Feb 26 Filed by: Teel Randy
3/2
08:57 pm
arvn
Form 4 ARVINAS, INC. For: Feb 27 Filed by: Houston John G
Low
Report
Form 4 ARVINAS, INC. For: Feb 27 Filed by: Houston John G
2/27
04:03 pm
arvn
Form 144 ARVINAS, INC. Filed by: Houston John G
Low
Report
Form 144 ARVINAS, INC. Filed by: Houston John G
2/25
05:10 pm
arvn
Form 4 ARVINAS, INC. For: Feb 23 Filed by: Loomis David K
Low
Report
Form 4 ARVINAS, INC. For: Feb 23 Filed by: Loomis David K
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/16
Form S-8 ARVINAS, INC.
18.8%
11/6 Form 424B5 ARVINAS, INC. 15.1%
6/4 Bayer teams up with biotech firm Arvinas in deal worth up to $750 million [Reuters (UK)] 11.3%
10/23 Arvinas Presents a Platform Update, Including Initial Data from the First Two Clinical Trials of PROTAC® Targeted Protein Degraders 10.5%
11/27 Arvinas to Present at the 31st Annual Piper Jaffray Healthcare Conference 8.8%
3/24 Form 4 ARVINAS, INC. For: Mar 23 Filed by: Houston John G 7.4%
7/25 Arvinas Strengthens Board of Directors with Addition of Leslie Norwalk 7.3%
11/12 Form 8-K ARVINAS, INC. For: Nov 06 6.9%
7/25 Form 8-K ARVINAS, INC. For: Jul 24 5.9%
9/12 Arvinas Inc (NASDAQ: ARVN) is now covered by analysts at BMO Capital Markets. They set an "outperform" rating on the stock. 5.8%
11/6 Form 424B5 ARVINAS, INC. 15.1%
6/4 Bayer teams up with biotech firm Arvinas in deal worth up to $750 million [Reuters (UK)] 11.3%
10/23 Arvinas Presents a Platform Update, Including Initial Data from the First Two Clinical Trials of PROTAC® Targeted Protein Degraders 10.5%
11/27 Arvinas to Present at the 31st Annual Piper Jaffray Healthcare Conference 8.8%
3/24 Form 4 ARVINAS, INC. For: Mar 23 Filed by: Houston John G 7.4%
7/25 Arvinas Strengthens Board of Directors with Addition of Leslie Norwalk 7.3%
11/12 Form 8-K ARVINAS, INC. For: Nov 06 6.9%
7/25 Form 8-K ARVINAS, INC. For: Jul 24 5.9%
9/12 Arvinas Inc (NASDAQ: ARVN) is now covered by analysts at BMO Capital Markets. They set an "outperform" rating on the stock. 5.8%
TOP News Decliners
3/16
Q4/2019 12/31/2019 EPS -0.560 ZacksConsensus N/A ActVsEst N/A - N/A
-18.4%
3/20 Form 4 ARVINAS, INC. For: Mar 18 Filed by: Margus Bradley Albert -11.5%
8/22 Arvinas Inc (NASDAQ: ARVN) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. -8.3%
8/5 Q2/2019 6/30/2019 EPS -0.550 ZacksConsensus N/A ActVsEst N/A - N/A -7.9%
10/1 Bayer and Arvinas Unveil Targeted Protein Degradation Joint Venture, Oerth Bio -7.1%
3/10 Arvinas Inc (NASDAQ: ARVN) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $52.00 price target on the stock. -7.1%
2/6 Form 8-K ARVINAS, INC. For: Jan 31 -6.3%
7/31 Form 3 ARVINAS, INC. For: Jul 29 Filed by: Peck Ronald -5.1%
7/16 Form 8-K ARVINAS, INC. For: Jul 15 -4.8%
10/7 Arvinas Inc (NASDAQ: ARVN) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. -4.5%
3/20 Form 4 ARVINAS, INC. For: Mar 18 Filed by: Margus Bradley Albert -11.5%
8/22 Arvinas Inc (NASDAQ: ARVN) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. -8.3%
8/5 Q2/2019 6/30/2019 EPS -0.550 ZacksConsensus N/A ActVsEst N/A - N/A -7.9%
10/1 Bayer and Arvinas Unveil Targeted Protein Degradation Joint Venture, Oerth Bio -7.1%
3/10 Arvinas Inc (NASDAQ: ARVN) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $52.00 price target on the stock. -7.1%
2/6 Form 8-K ARVINAS, INC. For: Jan 31 -6.3%
7/31 Form 3 ARVINAS, INC. For: Jul 29 Filed by: Peck Ronald -5.1%
7/16 Form 8-K ARVINAS, INC. For: Jul 15 -4.8%
10/7 Arvinas Inc (NASDAQ: ARVN) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. -4.5%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: